Understanding ApoB Testing and Statin Use for Heart Health

The Importance of ApoB Testing

Here’s the good news first: for the first time, doctors are now officially recommended to check a test called ApoB. This test provides a more accurate picture of your heart attack risk than standard cholesterol numbers alone. Many of us in preventive cardiology have been asking for this for years. It’s a real step forward.

However, two things in these new guidelines give me pause. You deserve to know about both before you leave your next doctor’s appointment.

Pause 1: The Diabetes Risk from Statins

Most randomized controlled statin studies only followed patients for 4–5 years. When we look at longer-term observational data, the risk of developing diabetes keeps climbing the longer someone takes a statin. This is not a reason to panic. For many people, the heart benefit still outweighs that risk. Observational studies often have undetected biases. But it is information you deserve before starting a medication you may be on for the rest of your life.

Even if the risk of diabetes is not as high as touted in some of the longer-term observational studies, it cannot be denied. Here’s the nuance that matters quite a bit: if you have no risk factors for diabetes going in—normal fasting blood sugar, healthy weight (BMI less than 30), and no high blood triglycerides—at least one research study suggested that your diabetes risk from statins may be lower while your heart protection remains real. If you already have several of those risk factors, the tradeoff may look very different.

Pause 2: The Lowered Bar for Statin Use

The “who should take a statin” bar has been lowered, but the evidence hasn’t caught up. The new guidelines recommend considering statins at lower and lower risk levels than ever before. The problem? The clinical trials that actually proved statins work enrolled much higher-risk patients. We’re recommending the medication to people who look different from the patients we studied.

What does that mean practically? At lower risk levels, you might need to treat anywhere from 67 to 150 people to prevent one heart attack over 10 years. Meanwhile, roughly 1 in 100 people on a moderate statin dose will develop diabetes as a result. The math gets tight. At those numbers, this should be a conversation, not a foregone conclusion.

At moderate risk levels, the picture shifts more meaningfully in favor of treatment. The benefit starts to clearly outweigh the harm for most people.

Understanding Statin Types and Their Risks

One more thing worth knowing: not all statins carry the same diabetes risk. Higher-intensity statins carry a meaningfully higher diabetes risk than moderate-intensity ones. This matters because at lower risk levels, a high-intensity statin may actually be more likely to cause harm than prevent a heart attack. Your doctor should be having this conversation with you about which statin and what dose, not just whether to start one.

Making Informed Decisions

Your Health, Your Choices

My bottom line is simple:

• ApoB testing is a genuine step forward: Ask for it by name.

• Starting statins at lower and lower risk thresholds is a conversation, not a foregone conclusion.

  
  

Your risk. Your tradeoffs. Your decision, with a doctor who takes the time to explain both sides. That’s what prevention should look like.

The Role of Preventive Care

Preventive care is essential for maintaining your health and preventing chronic diseases. By staying informed and proactive, you can make better decisions about your health. This approach empowers you to manage your well-being effectively.

Embracing Technology for Health Monitoring

In today's digital age, technology plays a crucial role in health monitoring. Wearable health monitors can provide real-time data about your body, helping you make informed decisions. These devices can track your heart rate, activity levels, and even sleep patterns. By integrating technology into your health routine, you can take charge of your wellness journey.

Conclusion: Take Charge of Your Health

In conclusion, understanding the implications of ApoB testing and statin use is vital for your heart health. Stay informed, ask questions, and engage in conversations with your healthcare provider. Your health is your responsibility, and making informed choices can lead to a longer, healthier life.

PreventionOnly HeartHealth KnowYourNumbers

References

1. Effects of Statin Therapy on Diagnoses of New-Onset Diabetes and Worsening Glycaemia in Large-Scale Randomised Blinded Statin Trials: An Individual Participant Data Meta-Analysis. Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk, Cholesterol Treatment Trialists’ (CTT) Collaboration. The Lancet. Diabetes & Endocrinology. 2024;12(5):306-319. doi:10.1016/S2213-8587(24)00040-8.

2. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Blumenthal RS, Morris PB, Gaudino M, et al. Journal of the American College of Cardiology. 2026;:S0735-1097(25)10254-4. doi:10.1016/j.jacc.2025.11.016.

3. Time- And Dose-Dependent Association of Statin Use With Risk of Clinically Relevant New-Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study. Ko MJ, Jo AJ, Kim YJ, et al. Journal of the American Heart Association. 2019;8(8):e011320. doi:10.1161/JAHA.118.011320.

4. Duration and Type of Statin Use and Long-Term Risk of Type 2 Diabetes Among Men and Women With Hypercholesterolaemia: Findings From Three Prospective Cohorts. Zhang Y, Li Y, Liu Y, et al. Diabetologia. 2025;68(8):1696-1708. doi:10.1007/s00125-025-06441-3.

5. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Newman CB, Preiss D, Tobert JA, et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019;39(2):e38-e81. doi:10.1161/ATV.0000000000000073.

6. Clinical Practice Guideline on Lipid Management for Cardiovascular Disease Risk Reduction. Paul Heidenreich, Lance Spacek, Neil Gregor, et al. Department of Veterans Affairs (2026).

7. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement. US Preventive Services Task Force, Mangione CM, Barry MJ, et al. JAMA. 2022;328(8):746-753. doi:10.1001/jama.2022.13044.

8. Effects of Statin Therapy on Diagnoses of New-Onset Diabetes and Worsening Glycaemia in Large-Scale Randomised Blinded Statin Trials: An Individual Participant Data Meta-Analysis. Cholesterol Treatment Trialists’ (CTT) Collaboration. Electronic address: ctt@ndph.ox.ac.uk, Cholesterol Treatment Trialists’ (CTT) Collaboration. The Lancet. Diabetes & Endocrinology. 2024;12(5):306-319. doi:10.1016/S2213-8587(24)00040-8.

9. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Newman CB, Preiss D, Tobert JA, et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019;39(2):e38-e81. doi:10.1161/ATV.0000000000000073.

10. Duration and Type of Statin Use and Long-Term Risk of Type 2 Diabetes Among Men and Women With Hypercholesterolaemia: Findings From Three Prospective Cohorts. Zhang Y, Li Y, Liu Y, et al. Diabetologia. 2025;68(8):1696-1708. doi:10.1007/s00125-025-06441-3.

11. Interpretation of the Evidence for the Efficacy and Safety of Statin Therapy. Collins R, Reith C, Emberson J, et al. Lancet (London, England). 2016;388(10059):2532-2561. doi:10.1016/S0140-6736(16)31357-5.

12. Statins Activate the NLRP3 Inflammasome and Impair Insulin Signaling via P38 and mTOR. Henriksbo BD, Tamrakar AK, Phulka JS, Barra NG, Schertzer JD. American Journal of Physiology. Endocrinology and Metabolism. 2020;319(1):E110-E116. doi:10.1152/ajpendo.00125.2020.

13. Statins Promote Interleukin-1β-Dependent Adipocyte Insulin Resistance Through Lower Prenylation, Not Cholesterol. Henriksbo BD, Tamrakar AK, Xu J, et al. Diabetes. 2019;68(7):1441-1448. doi:10.2337/db18-0999.

14. Statins Are Associated With Increased Insulin Resistance and Secretion. Abbasi F, Lamendola C, Harris CS, et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021;41(11):2786-2797. doi:10.1161/ATVBAHA.121.316159.

15. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care. 2026;49(Supplement_1):S216-S245. doi:10.2337/dc26-S010.

16. Lipid Management in Patients With Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. Newman CB, Blaha MJ, Boord JB, et al. The Journal of Clinical Endocrinology and Metabolism. 2020;105(12):dgaa674. doi:10.1210/clinem/dgaa674.